ID

22949

Description

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT00420927

Link

https://clinicaltrials.gov/show/NCT00420927

Keywords

Versions (1)
  1. 6/18/17 6/18/17 -
Uploaded on

June 18, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Rheumatoid Arthritis NCT00420927

English

Eligibility Rheumatoid Arthritis NCT00420927

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
subject must be 18 or older and in good health
Description

Age | Overall Well Being

Data type

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C3813622
subject must meet the definition of early rheumatoid arthritis (ra) defined by the 1987-revised american college of rheumatology (acr) classification criteria and had disease duration of less than 1 year from diagnosis
Description

Early Rheumatoid Arthritis disease length

Data type

boolean

Alias
UMLS CUI [1,1]
C3899278
UMLS CUI [1,2]
C0872146
subject must have a disease activity score (das28, based on c-reactive protein) greater than 3.2, at least 6 swollen joints out of the 66 assessed, and at least 8 tender joints out of the 68 assessed
Description

Disease activity score | C-reactive protein measurement | Swollen joint count | Tender joint count

Data type

boolean

Alias
UMLS CUI [1]
C2732493
UMLS CUI [2]
C0201657
UMLS CUI [3]
C0451521
UMLS CUI [4]
C0451530
subject must fulfill at least one of the following three criteria:
Description

Criteria Fulfill

Data type

boolean

Alias
UMLS CUI [1,1]
C0243161
UMLS CUI [1,2]
C1550543
rheumatoid factor positive
Description

Rheumatoid factor positive

Data type

boolean

Alias
UMLS CUI [1]
C0151379
greater than 1 joint erosion
Description

Joint erosion Quantity

Data type

boolean

Alias
UMLS CUI [1,1]
C0022417
UMLS CUI [1,2]
C0587240
UMLS CUI [1,3]
C1265611
anti-cyclic citrullinated peptide (ccp) antibody positive.
Description

Anti-cyclic citrullinated peptide antibody positive

Data type

boolean

Alias
UMLS CUI [1]
C2609056
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
subject has previously received systemic anti-tumor necrosis factor (tnf) therapy
Description

Anti-tumor necrosis factor therapy Systemic

Data type

boolean

Alias
UMLS CUI [1,1]
C0281481
UMLS CUI [1,2]
C0205373
subject has received any biologic or investigational therapy within 6 weeks prior to baseline
Description

Biological treatment | Investigational Therapy

Data type

boolean

Alias
UMLS CUI [1]
C1531518
UMLS CUI [2]
C0949266
subject has been previously treated with more than 2 disease-modifying antirheumatic drugs (dmards) or mtx, had been treated with intra-articular or parenteral administration of corticosteroids in preceding 4 weeks, or had undergone joint surgery within the preceding 2 months at joints to be assessed during the study.
Description

Disease-Modifying Antirheumatic Drugs Quantity | Methotrexate | intraarticular injection of corticosteroids | Adrenal Cortex Hormones Parenteral | Operation on joint | Joints Assessment Clinical Trial

Data type

boolean

Alias
UMLS CUI [1,1]
C0242708
UMLS CUI [1,2]
C1265611
UMLS CUI [2]
C0025677
UMLS CUI [3]
C2064783
UMLS CUI [4,1]
C0001617
UMLS CUI [4,2]
C1518896
UMLS CUI [5]
C0185132
UMLS CUI [6,1]
C0022417
UMLS CUI [6,2]
C1516048
UMLS CUI [6,3]
C0008976
Back to the top of the page

Similar models

Eligibility Rheumatoid Arthritis NCT00420927

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age | Overall Well Being
Item
subject must be 18 or older and in good health
boolean
C0001779 (UMLS CUI [1])
C3813622 (UMLS CUI [2])
Early Rheumatoid Arthritis disease length
Item
subject must meet the definition of early rheumatoid arthritis (ra) defined by the 1987-revised american college of rheumatology (acr) classification criteria and had disease duration of less than 1 year from diagnosis
boolean
C3899278 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Disease activity score | C-reactive protein measurement | Swollen joint count | Tender joint count
Item
subject must have a disease activity score (das28, based on c-reactive protein) greater than 3.2, at least 6 swollen joints out of the 66 assessed, and at least 8 tender joints out of the 68 assessed
boolean
C2732493 (UMLS CUI [1])
C0201657 (UMLS CUI [2])
C0451521 (UMLS CUI [3])
C0451530 (UMLS CUI [4])
Criteria Fulfill
Item
subject must fulfill at least one of the following three criteria:
boolean
C0243161 (UMLS CUI [1,1])
C1550543 (UMLS CUI [1,2])
Rheumatoid factor positive
Item
rheumatoid factor positive
boolean
C0151379 (UMLS CUI [1])
Joint erosion Quantity
Item
greater than 1 joint erosion
boolean
C0022417 (UMLS CUI [1,1])
C0587240 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Anti-cyclic citrullinated peptide antibody positive
Item
anti-cyclic citrullinated peptide (ccp) antibody positive.
boolean
C2609056 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Anti-tumor necrosis factor therapy Systemic
Item
subject has previously received systemic anti-tumor necrosis factor (tnf) therapy
boolean
C0281481 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
Biological treatment | Investigational Therapy
Item
subject has received any biologic or investigational therapy within 6 weeks prior to baseline
boolean
C1531518 (UMLS CUI [1])
C0949266 (UMLS CUI [2])
Disease-Modifying Antirheumatic Drugs Quantity | Methotrexate | intraarticular injection of corticosteroids | Adrenal Cortex Hormones Parenteral | Operation on joint | Joints Assessment Clinical Trial
Item
subject has been previously treated with more than 2 disease-modifying antirheumatic drugs (dmards) or mtx, had been treated with intra-articular or parenteral administration of corticosteroids in preceding 4 weeks, or had undergone joint surgery within the preceding 2 months at joints to be assessed during the study.
boolean
C0242708 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0025677 (UMLS CUI [2])
C2064783 (UMLS CUI [3])
C0001617 (UMLS CUI [4,1])
C1518896 (UMLS CUI [4,2])
C0185132 (UMLS CUI [5])
C0022417 (UMLS CUI [6,1])
C1516048 (UMLS CUI [6,2])
C0008976 (UMLS CUI [6,3])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial